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Abstract 
Background: Ofatumumab  (Arzerra®, Novartis) is a treatment for chronic lymphocytic leukemia refractory to fludara-
bine and alemtuzumab [double refractory (DR-CLL)]. Ofatumumab was licensed on the basis of an uncontrolled 
Phase II study, Hx-CD20-406, in which patients receiving ofatumumab survived for a median of 13.9 months. However, 
the lack of an internal control arm presents an obstacle for the estimation of comparative effectiveness.
Methods: The objective of the study was to present a method to estimate the cost effectiveness of ofatumumab 
in the treatment of DR-CLL. As no suitable historical control was available for modelling, the outcomes from non-
responders to ofatumumab were used to model the effect of best supportive care (BSC). This was done via a Cox 
regression to control for differences in baseline characteristics between groups. This analysis was included in a parti-
tioned survival model built in  Microsoft® Excel with utilities and costs taken from published sources, with costs and 
quality-adjusted life years (QALYs) were discounted at a rate of 3.5% per annum.
Results: Using the outcomes seen in non-responders, ofatumumab is expected to add approximately 0.62 life years 
(1.50 vs. 0.88). Using published utility values this translates to an additional 0.30 QALYs (0.77 vs. 0.47). At the list price, 
ofatumumab had a cost per QALY of £130,563, and a cost per life year of £63,542. The model was sensitive to changes 
in assumptions regarding overall survival estimates and utility values.
Conclusions: This study demonstrates the potential of using data for non-responders to model outcomes for BSC in 
cost-effectiveness evaluations based on single-arm trials. Further research is needed on the estimation of comparative 
effectiveness using uncontrolled clinical studies.
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Background
Ofatumumab  (Arzerra®, Novartis) is an anti-CD20 mon-
oclonal antibody, which is under investigation in a range 
of diseases. In the first indication studied—chronic lym-
phocytic leukemia refractory to fludarabine and alem-
tuzumab [double refractory (DR-CLL)] in an early study 
14 out of 33 (42%) patients had either a nodular partial 
response or a partial response [1].
Due to the lack of licensed (and established unlicensed) 
treatments in DR-CLL, the subsequent pivotal study, 
Hx-CD20-406, did not contain a control arm on the basis 
of clinical equipoise; as no other treatment had shown 
an effect in the condition, it was argued that it would 
have been unethical to deny patients the opportunity to 
experience results shown by ofatumumab in the previ-
ous study [2]. In Hx-CD20-406 ofatumumab was there-
fore administered to all patients with a dosing schedule 
determined by the dose finding program (a 300 mg load-
ing dose, followed by up to 11, 2000 mg doses)—a study 
design that was discussed extensively by the FDA review 
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[3]. As a result ofatumumab was administered to 59 
patients with DR-CLL enrolled from 2006 to 2008, who 
at the time of the interim analysis showed median sur-
vival of 13.7 months (subsequently a further 36 patients 
were enrolled, with median overall survival increasing 
to 13.9  months). The evidence from this interim analy-
sis of Hx-CD20-406 was deemed sufficient by regulators 
to grant ofatumumab marketing authorisation for CLL 
(subject to a follow-up study in this earlier line of dis-
ease), and in 2009 ofatumumab was granted a conditional 
licence for use by the European Medicines Agency, and 
accelerated approval by the US Food and Drug Adminis-
tration [4, 5].
The lack of a control arm presents a challenge for 
researchers seeking to estimate the comparative effect 
of treatment compared to current practice in DR-CLL. 
Although an ongoing follow-up study of ofatumumab 
established the efficacy of CLL in untreated patients 
[6], no further studies were planned (or have been con-
ducted) in DR-CLL. Where a relevant comparator is not 
included in the clinical study, indirect comparisons are 
recommended [7], but it is also possible to use an his-
torical control [8]; often when using single-arm trials a 
group of untreated patients seen in a similar setting can 
be identified and comparisons made. An example of 
such an evaluation is seen in imatinib for the treatment 
of chronic myeloid leukemia, where the efficacy of inter-
feron alpha was well characterised in published literature 
[8]. To account for differences between studies, different 
forms of adjustment can be applied which better match 
patient populations [9, 10].
In a systematic literature review for evidence in CLL, 
only one study was identified—Tam et  al. [11] reported 
a case series of 58 patients with DR-CLL, treated with 19 
different agents (including experimental agents, aggres-
sive combination chemotherapy, and other high-cost 
therapies not routinely available in UK practice) at an 
international centre of excellence (the MD Anderson 
Center, TX, USA). As the treatments administered in this 
study were very different from the supportive care offered 
in the UK and the patients fitter (due to being able to tol-
erate the treatments received), this did not represent a 
suitable historical control for the patients in Hx-CD20-
406. Equally as there are no randomized controlled trials, 
an indirect comparison was not possible.
Due to a lack of external data, we undertook a within-
study comparison of all ofatumumab-treated patients and 
non-responders to ofatumumab, assuming the outcomes 
of ofatumumab non-responders were similar to outcomes 
seen with best supportive care (BSC). This approach 
assumed that non-responders received neither benefit or 
harm from treatment and therefore their path would be 
representative of that achieved by no treatment. A further 
assumption was that it was possible to control for differ-
ences in baseline prognostic factors between respond-
ers and non-responders using individual patient data 
such that the non-responders were better matched to the 
whole population. Here we describe the methods, results, 
and limitations of this approach, using the motivating 
example of ofatumumab for the treatment of DR-CLL.
Methods
CLL is a chronic disease and, in the absence of effective 
treatment, will continue to progress (CLL is not a con-
dition where spontaneous remission is seen) [12, 13]. As 
no data was available on untreated patients, an assump-
tion was made that BSC would therefore represent no 
response. To implement this assumption in modelling, 
outcomes for BSC were represented by those of the 
patients who did not show a response to ofatumumab 
in HX-CD20-406 (the primary outcome of the trial, 
defined according to the working group on CLL guide-
lines [14]). In the study, the median overall survival (OS) 
was 13.7  months, with the difference in OS between 
responders and non-responders is shown in Fig. 1; non-
responders (n  =  22) survived a median of 9.8  months, 
whilst the median OS of responders (n  =  31) was not 
reached by the end of the 20-month study [15] based 
on landmark analysis at 12  weeks of patients who were 
able to be assessed. The comparison made in the model 
was therefore responders and non-responders to ofatu-
mumab treatment, compared to non-responders (who 
were assumed to represent BSC). This is as response can-
not be predicted a priori, so all patients must be treated 
to achieve the gains. We chose to use the interim data 
cut for the analyses presented here, as this represents the 
data that was available at the time decisions were made 
by both regulators and reimbursement agencies. This 
therefore gives more generalizable results, which also 
correspond with the published data [15].
Fig. 1 Overall survival for all patients vs. non-responders: Kaplan–
Meier, parametric curve fits, and Cox proportional hazards model
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To estimate progression free survival (PFS) and OS for 
ofatumumab, parametric survival functions were fitted 
to failure and progression time data from the all-patient 
group. PFS and OS in the BSC group were modelled 
by applying an estimated hazard ratio (HR) of survival 
between the non-responders and all-patient groups. The 
HRs were calculated based on a Cox proportional haz-
ards model, in order to account for any important differ-
ences between baseline characteristics of the two groups 
i.e. factors that may predict response, leading to imbal-
ances between the groups compared. In order to select 
the most appropriate parametric curve (from the lognor-
mal, log-logistic, exponential, Weibull and Gompertz), 
the Akaike information criterion (AIC) and visual inspec-
tion were used. In all cases the Weibull curve provided 
the best fit by having the lowest AIC and providing a 
good visual fit to all parts of the Kaplan–Meier curve (i.e. 
not systematically under- or over-predicting for any sec-
tion of the curve).
To model the non-responder group, the Cox regres-
sion included predictive covariates for sex, age, Rai stage, 
ECOG performance status, number of prior therapies, 
and years since diagnosis. This resulted in a change in the 
HR of 0.49, to an adjusted HR of 0.51 i.e. non-responders 
had had slightly less favorable prognostic characteris-
tics, resulting in the adjustment. As an alternative to this 
approach a sensitivity analysis was also conducted using 
parametric curve fits to both arms (in place of the Cox 
regression which implicitly assumes proportional haz-
ards). The resulting parametric curves and Cox regres-
sion results are shown in Figs.  1 and 2. All analyses 
were performed on the data available at the time (59 DR 
patients).
Ofatumumab was assumed to be administered in line 
with its licence, that is a 300 mg loading dose followed by 
up to 11 fortnightly doses of 2000 mg, administered until 
disease progression, death (if occurring prior to progres-
sion), or completion of the 24-week course. Patients who 
experienced disease progression were assumed to discon-
tinue therapy. Whilst residing in a particular health state, 
patients were assigned the health state cost and the util-
ity value linked to that health state. The effect of Grade 
3 and 4 adverse events on costs was also included in the 
model, with the incidence taken from Hx-CD20-406 [15]. 
The effects of adverse events on utility were not included 
in the model.
To extrapolate the results, a partitioned survival anal-
ysis model was constructed in  Microsoft® Excel 2003. 
The model had three health states: progression-free sur-
vival (PFS; the starting health state), progressed disease, 
and the absorbing state of death (Fig. 3). The proportion 
of patients in each health state over time is calculated 
using estimated survival distributions for PFS and over-
all survival (OS). The proportion in the progressed dis-
ease at any given time is calculated as the difference in 
OS and PFS at that time. This modeling approach has 
been used extensively in recent economic evaluations of 
novel cancer therapies. The model was then used to cal-
culate the cost effectiveness of ofatumumab versus BSC, 
standard of care for patients with DR-CLL in the UK at 
the time of the evaluation. As previously discussed BSC 
was represented in the model by the non-responders to 
ofatumumab.
The analysis took the perspective of the UK National 
Health Service (NHS), with a base year for costs of 2010 
[the year of the submission to the National Institute for 
Health and Care Excellence (NICE)]. The list price for 
ofatumumab was used in the analysis (£182 per 100  ml 
vial). Other costs were taken from NHS Reference Costs 
2008/2009 and the Unit Costs of Health and Social Care 
[16, 17]. Utility data were taken from a time trade-off 
study of 60 members of the general public by Ferguson 
Fig. 2 Progression free survival for all patients vs. non-responders: 
Kaplan–Meier, parametric curve fits, and Cox proportional hazards 
model Fig. 3 Economic model diagram
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et  al. [18] which used vignettes to derive preference 
weights for CLL health states—the only data available in 
this patient population. This study gave utility values of 
0.650 [95% Confidence Interval (CI) 0.597–0.703] for PFS 
and 0.470 (95% CI 0.415–0.525) for post-progression sur-
vival. A 10-year time horizon was used, after which 97% 
of patients in the ofatumumab arm, and 100% of patients 
in the BSC arm were projected to be in the ‘dead’ health 
state. Both costs and benefits were discounted on a daily 
model cycle, at a 3.5% yearly discounting rate, in line with 
NICE (2008) and UK Treasury (2009) guidelines [19, 20]. 
Life years were not discounted. Table 1 shows a list of the 
key inputs to the model, along with the sources.
Results
In the base case analysis (Table 2), ofatumumab was esti-
mated to provide an additional 0.617 life years (1.494 vs. 
0.877), and 0.301 additional quality-adjusted life years 
(QALYs) (0.770 vs. 0.469) compared to BSC. The esti-
mated gain in OS consisted of additional 0.163 life years 
(2.0  months) in the PFS state, and an additional 0.453 
life years (5.4  months) in the post-progression state. 
The results of the model closely matched those seen in 
Hx-CD20-406. Including extrapolation beyond the trial 
period, the model over predicted mean PFS (where data 
were mature) for non-responders by 5%, and under pre-
dicted PFS for all patients by 1%. Although the model fit-
ted the OS data well over the observed period, due to the 
immaturity of the data and low patient numbers, no firm 
conclusions can be reached regarding the appropriate-
ness of extrapolation.
The incremental cost of £39,186 consisted mostly of 
drug cost (£35,081). Based on these results, the incre-
mental cost-effectiveness ratio (ICER) was £130,563 per 
QALY, or £63,542 per life year gained. The difference 
between the cost per QALY and cost per life year can 
be attributed to the low utility experienced by patients, 
particularly in the post-progression health state (where 
utility was 0.470).
Results of sensitivity analyses (Table 3) show the model 
to be particularly sensitive to changes in the utility val-
ues used for health states—the wide confidence intervals 
from these estimates are due to the uncertainty in the 
original paper from which these were taken [18]. Using 
higher utility values decreased the ICER by £18,000, 
whilst lower utilities increased it by £82,000. The method 
of survival estimation for non-responders (to represent 
the BSC arm) was also important, with an increase in 
the HR of 20% for BSC reducing the ICER by £22,000, or 
including chromosomal deletions (clinically relevant pre-
dictors; however, with low numbers on each arm) in the 
Cox regression increasing the ICER by £15,000. When 
independent Weibull curve fits were used (instead of the 
Cox regression) the ICER increased by £13,000. However, 
it should be noted that the use of independent curve fits 
would not correct for any imbalance between groups at 
the baseline.
The only scenario the model was not sensitive to 
(showing only a 4% increase in the ICER) was a dou-
bling of the cost of drug administration (both pharmacist 
Table 1 Key costs and inputs to the economic model
BSC best supportive care
Parameter Value
Hazard ratio: overall survival, BSC vs. ofatumumab 1.8727
Hazard ratio: progression-free survival, BSC vs. ofatumumab 1.9608
Ofatumumab: cost of therapy initiation £2047
Ofatumumab: cost per 100 mg vial £182
Ofatumumab: concomitant medication cost £104
Ofatumumab: cost per chemotherapy administration £203
BSC: cost of therapy initiation £1470
All therapies: cost per month of routine management £158
Utility: progression-free survival 0.65
Utility: post-progression survival 0.47
Table 2 Disaggregated costs and  outcomes of  ofatu-
mumab compared to best supportive care
QALY quality-adjusted life years
Best support-
ive care
Ofatu-
mumab
Incremental
Costs
 Drug costs £0 £35,081 £35,081
 Administration costs £0 £1834 £1834
 Adverse event costs £1665 £1339 −£326
 Pre-progression 
healthcare costs
£2183 £3782 £1600
 Post-progression 
healthcare costs
£908 £1906 £998
 Total cost £4756 £43,942 £39,186
Life years
 Progression-free life 
years
0.379 0.543 0.163
 Post-progression life 
years
0.498 0.952 0.453
 Total life years 0.877 1.494 0.617
Quality-adjusted life years (QALYs)
 Progression-free 
QALYs
0.244 0.348 0.104
 Post-progression 
QALYs
0.225 0.421 0.196
 Total QALYs 0.469 0.770 0.301
Cost-effectiveness ratios
 Cost per life year £63,542
 Cost per QALY £130,563
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preparation cost and chemotherapy administration cost). 
This was included in order to simulate any increased time 
that may be needed for the preparation of a new special-
ist product, which would not be in widespread use (in the 
NICE submission for ofatumumab, there were an esti-
mated 13 patients per year in England and Wales) [21]. 
This increased the ICER by only £6000.
A probabilistic sensitivity analysis (Fig.  4) of 1000 
Monte-Carlo simulations demonstrated the majority of 
the uncertainty to be related to the magnitude of QALY 
gains, and not uncertainty in costs. This is due to the 
treatment course (the largest cost) being a fixed length 
and dosage; whilst there was substantial uncertainty in 
both the utility and clinical effectiveness estimates. In 
2.5% of scenarios, ofatumumab was dominated by BSC 
(i.e. it provided worse outcomes and higher costs), which 
reflects the degree of uncertainty in the clinical evidence 
for ofatumumab.
Discussion
The approach presented allows the estimation of cost 
effectiveness from a single-arm trial, where no histori-
cal control is available. However, there are a number of 
important limitations that cannot be addressed using 
the available data. The assumption implicit in the use of 
non-responders as a control arm was that the drug had 
no benefit or harm in these patients (which in this case is 
untestable due to the lack of control arm). If there was a 
disease-modifying benefit in non-responders (which did 
not reach the threshold for the definition of response), 
the effectiveness of ofatumumab versus BSC would be 
underestimated. The sensitivity analysis increasing the 
HR of BSC had a large impact on the ICER, showing 
the importance of the assumption that non-responders 
received no benefit: a 20% increase in the HR led to a 17% 
decrease in the ICER. It is therefore important to ensure 
the correct model is specified, and consider sensitivity 
analyses.
Conversely it also may be the case that the effective-
ness of the treatment arm is overestimated when non-
responders are used to estimate the outcomes for BSC. 
If responders had better prognostic indicators (either 
observed or unobserved), then it may be that patients 
who were responders would have performed better, 
regardless of treatment. Although the two groups were 
fairly well balanced in observable baseline characteris-
tics, a lower proportion of responders exhibited deletion 
of chromosome 17p [15]. In a sensitivity analysis where 
the negative prognostic factors of chromosome 17p or 
11q deletion were included in the Cox regression (used to 
estimate the HR for non-responders vs. responders) the 
ICER increased by 12%. However, the data used to build 
Table 3 Results of sensitivity analyses
QALY quality-adjusted life year, costs and QALYs discounted at 3.5%, ICER incremental cost effectiveness ratio
Treatment Total costs Life years QALYs Incremental 
costs
Incremental 
life years
Incremental 
QALYs
Cost per life 
year gained
Cost per QALY 
gained
Base case results
 Best supportive care £4756 0.877 0.469 – – – – –
 Ofatumumab £43,942 1.494 0.770 £39,186 0.617 0.301 £63,542 £130,563
Sensitivity analysis: utility values set to ‘following first-line treatment’ (progression-free survival 0.777 & post-progression 0.540)
 Best supportive care £4756 0.877 0.551 – – – – –
 Ofatumumab £43,942 1.494 0.770 £39,186 0.617 0.219 £63,542 £112,067
Sensitivity analysis: utility values set to ‘following final treatment’ (progression-free survival 0.428 & post-progression 0.279)
 Best supportive care £4756 0.877 0.294 – – – – –
 Ofatumumab £43,942 1.494 0.770 £39,186 0.617 0.476 £63,542 £211,918
Sensitivity analysis: independent curve fit used for control arm
 Best supportive care £4884 0.952 0.497 – – – – –
 Ofatumumab £43,942 1.494 0.770 £39,058 0.542 0.273 £72,080 £143,402
Sensitivity analysis: alternative Cox regression including 17p and 11q chromosomal deletions
 Best supportive care £4876 0.945 0.501 – – – – –
 Ofatumumab £43,942 1.494 0.770 £39,066 0.550 0.269 £71,076 £145,524
Sensitivity analysis: hazard rate on best supportive care increased by 20%
 Best supportive care £4524 0.748 0.405 – – – – –
 Ofatumumab £43,942 1.494 0.770 £39,419 0.746 0.365 £52,837 £108,205
Sensitivity analysis: ofatumumab administration time doubled
 Best supportive care £4756 0.945 0.405 – – – – –
 Ofatumumab £45,694 1.494 0.770 £40,938 0.617 0.301 £66,383 £136,399
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the Cox regression for this analysis were based on low 
patient numbers for chromosomal deletions (17p dele-
tion n = 10 for responders and n = 7 for non-responders, 
11q deletion n =  9 for responders and n =  15 for non-
responders). This in turn highlights another limitation of 
the analysis; although attempts have been made to cor-
rect for any imbalances at baseline, responder status may 
have been linked to a characteristic not included in the 
Cox regression, or to an unobservable characteristic.
These two confounding factors (potential overestima-
tion of the outcomes from BSC and overestimation of 
the treatment effect) may affect the analysis simultane-
ously, resulting in an overall bias of an unknown magni-
tude and unknown direction, which would affect not only 
time to event estimates, but also utility and resource use 
estimates. There is also a potential issue regarding arti-
ficially low estimates of standard errors; a subset of the 
all-patients group is used as a comparator, making the 
comparator group dependent on the treatment group, 
violating the assumptions needed for statistical inference 
of standard error estimation—further research on this 
topic would be required.
Results of the modelling in this case suggest that ofa-
tumumab allows patients additional PFS and OS, based 
on the results of the Hx-CD20-406 trial and using non-
responders to treatment as proxy for the outcomes of 
BSC. At typical UK willingness-to-pay thresholds, ofa-
tumumab is not considered cost effective from the per-
spective of the NHS when analysed at list price [15]. 
Although, the manufacturer (at the time of the submis-
sion GlaxoSmithKline) proposed a patient access scheme 
in the submission to NICE, this was not evaluated in this 
paper as it was a confidential discount scheme.
The use of single-arm trial data also raises questions 
regarding the presentation of economic evaluations. In 
published appraisals, authors are encouraged to perform 
a sensitivity analysis, varying parameters within the 95% 
confidence intervals to generate a tornado diagram, and 
also to perform a probabilistic sensitivity analysis [22]. 
When using uncontrolled studies, performing only one-
way sensitivity analyses and a probabilistic analysis does 
not truly characterise the uncertainty present in the clini-
cal evidence. Although this issue is not unique to studies 
based on single-arm trials, the problem is more relevant 
as there is an underlying assumption that the clinical data 
used is suitable for comparison. In addition to analyses 
on the sensitivity of the model to parameter changes, 
scenario analyses are also needed where the fundamen-
tal assumptions underpinning the analysis are varied. In 
the ofatumumab model for example, it is not sufficient 
to test alternative curve fits to the control group, but the 
survival of the control group should also be explored 
Fig. 4 Scatterplot of probabilistic sensitivity analysis (1000 simulations)
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(not seen as fixed data to which a variety of fits should be 
made).
Although there were a lack of options for the modelling 
of uncontrolled data, one option that it was not possible 
explore in this example (due to a lack of data availability) 
is to use data on patients who have failed on the previ-
ous line of treatment. In the case of ofatumumab, this 
would be patients who failed treatment in the alemtu-
zumab registration trial conducted by Fraser et  al. [12]. 
These patients would have become double refractory on 
alemtuzumab failure, and thus been eligible for treatment 
with ofatumumab (had it been available). The treatment 
received would then have been ‘standard of care’ as ofa-
tumumab was not available, effectively making this group 
an historical control. Although there are issues regarding 
data sharing between companies to allow such compari-
sons, a collaboration between Roche, GlaxoSmithKline, 
Sanofi and Boehringer Ingelheim and ViiV Healthcare 
has begun to provide researchers with access to data from 
completed clinical trials [23]. If this initiative is joined by 
other companies, researchers would be able to complete 
analyses that are not currently possible due to limitations 
in reporting in published papers—with patients being the 
ultimate beneficiaries.
In the process of modelling a single-arm trial, we recog-
nise the limitations of previous approaches and also those 
of the approach we have used. Many questions remain 
regarding how best to perform cost-effectiveness analyses 
using single-arm trials; research is needed to show which 
methodological options are available, and suitable for 
use. The method proposed in this paper (of comparison 
to non-responders) can be tested in haematology clini-
cal trials with control arms, and also simulation studies. 
Datasets where response has objective criteria (for exam-
ple, blood counts) would allow a comparison between 
non-responders and placebo-treated patients. Further 
research on single-arm trials would also be valuable for 
other areas in which they are commonly used, such as 
orphan diseases. This is particularly important as even 
where published data can be used as an historical con-
trol, these can become invalidated by the introduction of 
new treatments. For example, the use of beta-interferons 
in multiple sclerosis, or targeted therapies in early-stage 
breast cancer have drastically changed the natural history 
of the disease and may render the use of previously pub-
lished studies as historical controls invalid.
Conclusions
In this paper, we describe an approach for presenting a 
cost-effectiveness comparison where comparative data 
are not available from either a control arm or an his-
torical control. The method avoids the problem of naïve 
comparisons between single-arm trials with differences 
in settings and/or patient characteristics. While the 
proposed method has limitations (most notably the 
assumptions made regarding the disease course of non-
responders, and independence of observations), it does 
allow the estimation of cost effectiveness in  situations 
where otherwise it would be impossible. This, in turn, 
allows decision-making bodies (such as NICE) to use a 
best estimate in their deliberations, mindful of the uncer-
tainty in analyses.
There is still a substantial need for research in eco-
nomic analyses using outcomes from single-arm trials. 
Gaps include validation of the use of non-responders as a 
control arm in other datasets, and guidance on methods 
to estimate comparative efficacy using single-arm trials.
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